Showing 6041-6050 of 8712 results for "".
- Ortho Dermatologics Opens Applications for 2021 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-applications-for-2021-aspire-higher-scholarship-program/2460683/Ortho Dermatologics opened the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals. &ldquo
- FDA Clears CellFX from Pulse Bioscienceshttps://practicaldermatology.com/news/fda-clears-cellfx-from-pulse-biosciences/2460682/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon begin in the US with a select group of leaders in aesthetic dermatology. The
- Second-Draw PPP Loans: What Dermatologists Should Knowhttps://practicaldermatology.com/news/second-draw-ppp-loans-what-dermatologists-should-know/2460680/By Mark Schmidt, CEO, Fund-Ex Solutions Group Dermatologists have proven their resiliency throughout the pandemic, and now more help is here with another round of funding through the Paycheck Protection Program (PPP). The Economic Aid Act reopened the Small Business Administratio
- Bristol Myers Squibb: Positive Topline Results Pivotal Phase 3 Psoriasis Study of Deucravacitinibhttps://practicaldermatology.com/news/bristol-myers-squibb-positive-topline-results-pivotal-phase-3-psoriasis-study-of-deucravacitinib/2460678/Bristol Myers Squibb shared positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to s
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- People with Severe Atopic Dermatitis May Have Increased Risk of Death from Several Causeshttps://practicaldermatology.com/news/people-with-severe-atopic-dermatitis-may-have-increased-risk-of-death-from-several-causes/2460673/Although there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Im
- Dominion Aesthetic Technologies Closes $23.7 Million Series B Financing to Accelerate the Commercialization of EONhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-closes-237-million-series-b-financing-to-accelerate-the-commercialization-of-eon/2460672/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Survey: Teledermatology Appointments Are Suitable Alternatives to Office Visitshttps://practicaldermatology.com/news/survey-teledermatology-appointments-are-suitable-alternatives-to-office-visits/2460669/The majority of dermatology patients find telehealth appointments to be a suitable alternative to in-person office visits, according to a survey in the Journal of Drugs in Dermatology.
- Allergan Aesthetics Introduces CoolSculpting Elitehttps://practicaldermatology.com/news/allergan-aesthetics-introduces-coolsculpting-elite/2460667/Allergan Aesthetics, an AbbVie company, is launching CoolSculptingElite, its next generation fat reduction system with applicators designed to complement the body's natural curves. The system will launch with a new applicator collection, which includes seven different shapes a